Industry and Technology Minister Mustafa Varank inspected the facility, which will produce medical consumables such as vacuum blood tube, syringe and serum set with domestic facilities and can prevent imports of $ 50 million annually.
Minister Varank visited TTT World within the Sıla Group and received information about the company's investments.
With the outbreak of the new type of coronavirus (Kovid-19), it became clear how critical the production of consumables is in the healthcare industry. Benefiting from the investment incentives of the Ministry of Industry and Technology, Ankara company started production in a short time in this context. Companies that are critical blood supplies vacuum tubes, syringes, drip, needle tip, branül, gloves and aims to reduce dependence on foreign produce blood bags in Turkey. Starting production, the company will follow a 3-phase project and employ 900 people when the investments are completed.
In the first phase, vacuum blood tubes, syringes and serum sets started to be produced. By the end of the year, 450 million vacuum blood tubes, 500 million injectors and 75 million serum sets will be produced.
Thus, these products, which are mostly imported ready-made, will be produced locally. In addition to meeting the need in the domestic market, it is planned to export these items next year.
When the second phase, in which the needle tip, branch and surgical sutures will be localized, it is aimed to produce 1,5 billion needles per year.
In the last phase investment is still not produced domestically will be possible to make blood bags and gloves in Turkey.
Unlike its counterparts in the market, the company can produce blood tubes with a ready-made barcode or data matrix. This saves additional labeling costs.
Another innovative study will be the production of the gel, which is mandatory to use in some tubes. These gels make it possible to keep the blood taken in the tubes under appropriate conditions until testing. The company aims to completely localize this gel with chemical properties.
The system created by the company with its sub-suppliers also reflects an innovative perspective. The developed business model brings growth with suppliers. The components of the blood tube are produced by guaranteeing purchase to different SMEs. Thus, it is aimed to strengthen suppliers and reach higher capacities in production through clustering.
“DOMESTIC COMPONENTS SHOULD BE PREFERRED”
Minister Varank said in a statement after his visit that the plant started production 2 months ago with the incentives of the Ministry of Industry and Technology.
Production at the facility in blood tubes made Varank stating that Turkey's foreign trade deficit of $ 50 million, for the manufacture of medical products with an investment in this area was emphasized that a country that aspires to be self-sufficient.
“WE STARTED DOMESTIC WORKS BEFORE KOVID-19”
Varank pointed out that together with Kovid-19, the value of domestic production and self-sustainability is understood all over the world, “We have initiated many programs in the field of localization before coronavirus. We have intensified our efforts to increase our production capabilities in high-tech products and to become a self-sufficient country in every field of industry. ” said.
Pointing out that such facilities play an important role in closing the foreign trade deficit, Varank said:
"These products are produces by foreign firms and their counterparts used in Turkey. We need to create awareness of the use of local counterparts in hospitals and laboratories. As a state, we are applying a 15 percent price advantage to the local product in public tenders. ”
“WE ARE LOOKING TO THE HEALTH INDUSTRY AS A NATIONAL SECURITY POLICY”
Minister Varank pointed out the importance they attach to the health industry and said, “We look at the health products industry as a national security policy. As you know, the power of countries in the field of war is directly related to their defense industry capabilities. We have seen how critical and strategic the health industry is in this epidemic. With the epidemic, many countries were closed. They put the needs of their own citizens in the first place and stopped exporting. For example, we could not get the mask filters we imported from Germany and France before. We immediately localized these filters and eliminated foreign dependency without wasting time. We have lowered our domestic intensive care respirator from the production line in just 2 weeks. We breathed both our country and the world with this product. Even these two examples alone show how strong our industry's flexibility, adaptability and innovative capabilities are. We will continue to replicate such examples. ” found the assessment.
“RESISTANCE OF INDUSTRY WILL INCREASE”
Reminding that medical production is considered as "priority investment" in the incentive, Varank said that they will continue their support to the company.
Pointing to the importance of increasing the localization rates, Varank said, “As the localization rates increase, our industry will be more resistant. Our vulnerability in times of crisis like the epidemic will decrease. As the foreign trade deficit decreases, our country's economy will strengthen and continue on its way. ” used expressions.
“INCENTIVE PROCESSES PROCESSED EXTREMELY FAST”
Sıla Group Chairman İhsan Şahin stated that they started the production of injectors and blood tubes within the scope of the investment, and that they will complete the first phase of the investment by producing serum sets at the end of the month.
Stating that they will complete all phases within 2 years, Şahin said that they will benefit from advantages such as tax, SSI withholding and credit interest discount within the scope of the incentive.
Şahin pointed out that investment incentive processes work extremely fast and thanked President Recep Tayyip Erdoğan and Minister Varank.
Source: Sanayi gov.tr